Literature DB >> 16539620

New cellular and molecular immune pathways in ischemia/reperfusion injury.

P Boros1, J S Bromberg.   

Abstract

Ischemia/reperfusion injury (IRI) is a multi-factorial antigen-independent inflammatory condition that profoundly affects both early and long-term function of the allograft as suggested by both clinical and experimental data. In recent years, the acute phase of IRI has been increasingly viewed as part of the innate immune response. Identification of novel molecular pathways and new insights into the mechanisms of known mediators of IRI have established links among innate immunity, adaptive immune responses and organ regeneration, and thus long-term graft function. This review approaches these novel aspects of IRI in the context of solid organ transplantation, presenting data on new observations with kidney, liver and heart allografts.

Entities:  

Mesh:

Year:  2006        PMID: 16539620     DOI: 10.1111/j.1600-6143.2005.01228.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  91 in total

1.  Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.

Authors:  Hye J Kim; Jong S Lee; Jung D Kim; Hee J Cha; Ahra Kim; Sun K Lee; Sang C Lee; Byoung S Kwon; Robert S Mittler; Hong R Cho; Byungsuk Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Assessment of kidney organ quality and prediction of outcome at time of transplantation.

Authors:  Thomas F Mueller; Kim Solez; Valeria Mas
Journal:  Semin Immunopathol       Date:  2011-01-28       Impact factor: 9.623

3.  TLR2 and NODs1 and 2 cooperate in inflammatory responses associated with renal ischemia reperfusion injury.

Authors:  Sashi G Kasimsetty; Alana Hawkes; Kayvan Barekatain; Elizabeth Soo; Alexander K Welch; Dianne B McKay
Journal:  Transpl Immunol       Date:  2019-11-22       Impact factor: 1.708

Review 4.  Role of nitric oxide in hepatic ischemia-reperfusion injury.

Authors:  Arunotai Siriussawakul; Ahmed Zaky; John D Lang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

5.  Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre.

Authors:  Roberto Hernandez-Alejandro; Yves Caumartin; Cameron Chent; Mark A Levstik; Douglas Quan; Norman Muirhead; Andrew A House; Vivian McAlister; Anthony M Jevnikar; Patrick P W Luke; William Wall
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

6.  Ischemic preconditioning attenuates acute lung injury after partial liver transplantation.

Authors:  Qinlong Liu; Hasibur Rehman; Yasodha Krishnasamy; John J Lemasters; Zhi Zhong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-04-20

7.  IL-18 contributes to renal damage after ischemia-reperfusion.

Authors:  Huiling Wu; Melissa L Craft; Peng Wang; Kate R Wyburn; Gang Chen; Jin Ma; Brett Hambly; Steven J Chadban
Journal:  J Am Soc Nephrol       Date:  2008-09-24       Impact factor: 10.121

8.  Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation.

Authors:  Tarek Alhamad; Daniel C Brennan; Zaid Brifkani; Huiling Xiao; Mark A Schnitzler; Vikas R Dharnidharka; David Axelrod; Dorry L Segev; Krista L Lentine
Journal:  Transplantation       Date:  2016-05       Impact factor: 4.939

9.  IRF-1 promotes inflammation early after ischemic acute kidney injury.

Authors:  Yanxia Wang; Reji John; Jianlin Chen; James A Richardson; John M Shelton; Michael Bennett; Xin J Zhou; Glenn T Nagami; Ying Zhang; Qing Qing Wu; Christopher Y Lu
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

Review 10.  Soluble biglycan as a biomarker of inflammatory renal diseases.

Authors:  Louise Tzung-Harn Hsieh; Madalina-Viviana Nastase; Jinyang Zeng-Brouwers; Renato V Iozzo; Liliana Schaefer
Journal:  Int J Biochem Cell Biol       Date:  2014-08-01       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.